Variants of CRISPR from Prevotella and Francisella 1 (Cpf1)
AssigneeThe General Hospital Corporation
InventorsJ. Keith Joung, Benjamin Kleinstiver
Life of this patent
Estimating the term…
Abstract
Engineered CRISPR from Prevotella and Francisella 1 (Cpf1) nucleases with altered and improved target specificity and their use in genomic engineering, epigenomic engineering, genome targeting, genome editing, and in vitro diagnostics.
Claims10
A method of altering the genome of a cell, the method comprising expressing in the cell, or contacting the cell with, an isolated Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) from Prevotella and Francisella 1 (Cpf1) protein, wherein the protein is from Acidaminococcus sp. BV3L6 (AsCpf1), comprising a sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:2, with a mutation of N282A in SEQ ID NO:2, and a guide RNA having a region complementary to a selected portion of the genome of the cell, whereby the genome of the cell is altered.
A method of altering a double stranded DNA (dsDNA) molecule, the method comprising contacting the dsDNA molecule with, an isolated Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) from Prevotella and Francisella 1 (Cpf1) protein, wherein the protein is from Acidaminococcus sp. BV3L6 (AsCpf1), comprising a sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:2, with a mutation of N282A in SEQ ID NO:2, and a guide RNA having a region complementary to a selected portion of the dsDNA molecule, whereby the genome of the dsDNA molecule is altered.
Dependencies are inferred from the claim text.